Literature DB >> 9020150

Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis.

M Dolan1, T Horchar, B Rigatti, J R Hassell.   

Abstract

Perlecan is primarily a heparan sulfate containing proteoglycan found in all basement membranes. Rotary shadowed images of perlecan show it to contain three glycosaminoglycan (GAG) side chains extending from one end of its core protein. Domain I is at the N terminus of perlecan and contains three closely spaced Ser-Gly-Asp sequences that may serve in GAG attachment. We evaluated the serines in these three sequences for GAG attachment by preparing a cDNA construct encoding for the N-terminal half (domains I, II, and III) of perlecan and then a series of constructs containing deletions and mutations within domain I of the domain I/II/III construct, expressing these constructs in COS-7 cells, and then analyzing the recombinant product for GAG side chains and GAG type. The results showed that all three serine residues in the Ser-Gly-Asp sequences in domain I can accept both chondroitin and heparan sulfate side chains but that a cluster of acidic residues N-terminal to these sequences is the primary determinant responsible for targeting these sites for heparan sulfate. Furthermore, there are two elements that can enhance heparan sulfate synthesis at a targeted site: 1) the presence of a the SEA module in the C-terminal region of domain I and 2) the presence of multiple acceptors in close proximity. These results indicate that the proportion of heparan and chondroitin sulfate at any one site in domain I of perlecan is regulated by multiple factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9020150     DOI: 10.1074/jbc.272.7.4316

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation.

Authors:  Karin Tran-Lundmark; Phan-Kiet Tran; Gabrielle Paulsson-Berne; Vincent Fridén; Raija Soininen; Karl Tryggvason; Thomas N Wight; Michael G Kinsella; Jan Borén; Ulf Hedin
Journal:  Circ Res       Date:  2008-07-03       Impact factor: 17.367

Review 2.  Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?

Authors:  R D Rosenberg; N W Shworak; J Liu; J J Schwartz; L Zhang
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

3.  Basement membrane and stroke.

Authors:  Yao Yao
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-18       Impact factor: 6.200

4.  A role for the perlecan protein core in the activation of the keratinocyte growth factor receptor.

Authors:  G Ghiselli; I Eichstetter; R V Iozzo
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

5.  A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.

Authors:  Mary C Farach-Carson; Anissa J Brown; Megan Lynam; Jeffrey B Safran; Daniel D Carson
Journal:  Matrix Biol       Date:  2007-10-10       Impact factor: 11.583

Review 6.  Role of perlecan in skeletal development and diseases.

Authors:  John Hassell; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

Review 7.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

8.  The core protein of growth plate perlecan binds FGF-18 and alters its mitogenic effect on chondrocytes.

Authors:  Simone M-L Smith; Leigh A West; John R Hassell
Journal:  Arch Biochem Biophys       Date:  2007-10-22       Impact factor: 4.013

9.  Dynamic expression patterns of ECM molecules in the developing mouse olfactory pathway.

Authors:  Elaine L Shay; Charles A Greer; Helen B Treloar
Journal:  Dev Dyn       Date:  2008-07       Impact factor: 3.780

10.  Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney.

Authors:  Maarit Rossi; Hiroyuki Morita; Raija Sormunen; Sari Airenne; Marjut Kreivi; Ling Wang; Naomi Fukai; Bjorn R Olsen; Karl Tryggvason; Raija Soininen
Journal:  EMBO J       Date:  2003-01-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.